These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 7938907)
41. Reduction of abnormal behavioral response to brief restraint by information from other mice in dystrophin-deficient mdx mice. Yamamoto K; Yamada D; Kabuta T; Takahashi A; Wada K; Sekiguchi M Neuromuscul Disord; 2010 Aug; 20(8):505-11. PubMed ID: 20558066 [TBL] [Abstract][Full Text] [Related]
42. alpha-Methylprednisolone promotes skeletal myogenesis in dystrophin-deficient and control mouse cultures. Metzinger L; Passaquin AC; Warter JM; Poindron P Neurosci Lett; 1993 Jun; 155(2):171-4. PubMed ID: 8377947 [TBL] [Abstract][Full Text] [Related]
43. A possible role of tryptase in angiogenesis in the brain of mdx mouse, a model of Duchenne muscular dystrophy. Nico B; Marzullo A; Corsi P; Vacca A; Roncali L; Ribatti D Neuroscience; 2004; 123(3):585-8. PubMed ID: 14706770 [TBL] [Abstract][Full Text] [Related]
44. The pituitary-muscle axis in mdx dystrophic mice. Anderson JE; Liu L; Kardami E; Murphy LJ J Neurol Sci; 1994 May; 123(1-2):80-7. PubMed ID: 8064326 [TBL] [Abstract][Full Text] [Related]
45. A new genetic variant of mdx mice: study of the phenotype. Krivov LI; Stenina MA; Yarygin VN; Polyakov AV; Savchuk VI; Obrubov SA; Komarova NV Bull Exp Biol Med; 2009 May; 147(5):625-9. PubMed ID: 19907755 [TBL] [Abstract][Full Text] [Related]
46. Yields of muscle from myogenic cells implanted into young and old mdx hosts. Morgan JE; Fletcher RM; Partridge TA Muscle Nerve; 1996 Feb; 19(2):132-9. PubMed ID: 8559160 [TBL] [Abstract][Full Text] [Related]
47. Mast cell proliferation and alterations in bFGF amount and localization are involved in the response of muscle to dystrophin deficiency in hypertrophic feline dystrophy. Seiler G; Welle M; Busato A; Lin S; Gaschen FP Neuromuscul Disord; 2001 Jan; 11(1):56-71. PubMed ID: 11166167 [TBL] [Abstract][Full Text] [Related]
48. Emergent presentation of a cat with dystrophin-deficient muscular dystrophy. Gambino AN; Mouser PJ; Shelton GD; Winand NJ J Am Anim Hosp Assoc; 2014; 50(2):130-5. PubMed ID: 24446404 [TBL] [Abstract][Full Text] [Related]
52. Tests for local toxicity of intramuscular drug preparations. Comparison of in vivo and in vitro findings. Surber C; Dubach UC Arzneimittelforschung; 1989 Dec; 39(12):1586-9. PubMed ID: 2624610 [TBL] [Abstract][Full Text] [Related]
53. Golden retriever muscular dystrophy: monitoring for success. Kornegay JN; Sharp NJ; Bartlett RJ; Van Camp SD; Burt CT; Hung WY; Kwock L; Roses AD Adv Exp Med Biol; 1990; 280():267-72. PubMed ID: 2248147 [No Abstract] [Full Text] [Related]
55. Mdx mouse as therapeutic model system: development and implementation of phenotypic monitoring. Hudecki MS; Pollina CM Adv Exp Med Biol; 1990; 280():251-63; discussion 263-5. PubMed ID: 2248146 [No Abstract] [Full Text] [Related]
57. Local tissue damage after intramuscular injections in rabbits and pigs: quantitation by determination of creatine kinase activity at injection sites. Diness V Acta Pharmacol Toxicol (Copenh); 1985 May; 56(5):410-5. PubMed ID: 4036633 [TBL] [Abstract][Full Text] [Related]
58. [Risks of serial intramuscular injections]. Gabka J Dtsch Z Mund Kiefer Gesichtschir; 1989; 13(2):121-8. PubMed ID: 2598515 [TBL] [Abstract][Full Text] [Related]